Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:02:34 EDT Wed 16 Oct 2024
Enter Symbol
or Name
USA
CA



Q:SPRY - ARS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SPRY - Q2.315.26·15.500.515.23+0.281.91,025.614,9307,23815.05  15.50  14.2216.50  3.35Oct 15Sep 2315 min RT 2¢

Recent Trades - Last 10 of 7238
Time ETExPriceChangeVolume
18:23:41Q15.3870.437200
18:02:38Q15.350.4016
18:00:58Q15.350.4016
17:51:58Q15.270.3223
17:51:58Q15.260.3112
17:51:58Q15.260.3164
17:10:33Q15.350.4075
17:02:47Q15.400.4515
16:51:38Q15.240.2930
16:40:34Q15.230.28943

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-23 08:00U:SPRYNews ReleaseARS Pharmaceuticals Announces U.S. Availability of neffy(TM) (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
2024-09-10 16:05U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
2024-09-09 16:47U:SPRYNews ReleaseARS Pharmaceuticals Submits sNDA to FDA for neffy(TM) 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
2024-09-04 08:00U:SPRYNews ReleaseARS Pharmaceuticals Launches Pre-Ordering Services for neffy(TM) to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
2024-08-26 09:29U:SPRYNews ReleaseEURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
2024-08-09 12:50U:SPRYNews ReleaseARS Pharmaceuticals Receives FDA Approval of neffy(TM) (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
2024-08-07 09:01U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
2024-08-06 16:01U:SPRYNews ReleaseARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
2024-06-28 06:30U:SPRYNews ReleaseARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
2024-05-09 16:05U:SPRYNews ReleaseARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
2024-04-30 09:01U:SPRYNews ReleaseARS Pharmaceuticals Submits Response for neffy(TM) (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
2024-04-03 09:01U:SPRYNews ReleaseARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy(TM) (Epinephrine Nasal Spray)
2024-03-21 16:05U:SPRYNews ReleaseARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-07 16:05U:SPRYNews ReleaseARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy(TM) Investor Day
2024-03-06 09:01U:SPRYNews ReleaseARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
2024-02-26 09:01U:SPRYNews ReleaseARS Pharmaceuticals announces neffy(TM) meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
2024-02-22 09:01U:SPRYNews ReleaseARS Pharmaceuticals to Host Virtual neffy ‚ ® Investor Day on March 7, 2024
2024-02-20 09:01U:SPRYNews ReleaseARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy ‚ ® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA ¢ € ™s Complete Response Letter
2024-02-05 09:01U:SPRYNews ReleaseARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy ‚ ® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
2023-12-11 05:32U:SPRYNews ReleaseINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm